



OPEN ACCESS

EDITED AND REVIEWED BY
Zhiwei Xu,
The University of Queensland, Australia

*CORRESPONDENCE
Kuang-Hui Yu
✉ gout@adm.cgmh.org.tw

SPECIALTY SECTION
This article was submitted to
Autoimmune and Autoinflammatory
Disorders: Autoimmune Disorders,
a section of the journal
Frontiers in Immunology

RECEIVED 01 December 2022
ACCEPTED 07 December 2022
PUBLISHED 16 January 2023

CITATION
Chen D-P, Lin W-T and Yu K-H (2023)
Corrigendum: Investigation of the
association between the genetic
polymorphisms of co-stimulatory system
and systemic lupus erythematosus.
Front. Immunol. 13:1113152.
doi: 10.3389/fimmu.2022.1113152

COPYRIGHT
© 2023 Chen, Lin and Yu. This is an open-
access article distributed under the terms of
the [Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that
the original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Corrigendum: Investigation of the association between the genetic polymorphisms of co-stimulatory system and systemic lupus erythematosus

Ding-Ping Chen^{1,2}, Wei-Tzu Lin¹ and Kuang-Hui Yu^{3*}

¹Department of Laboratory Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan, ²Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Taoyuan, Taiwan, ³Division of Rheumatology, Allergy, and Immunology, Chang Gung University and Memorial Hospital, Taoyuan, Taiwan

KEYWORDS

systemic lupus erythematosus (SLE), co-stimulatory/co-inhibitory molecules, single nucleotide polymorphism (SNP), autoimmune disease (AD), association

A Corrigendum on

Investigation of the association between the genetic polymorphisms of the co-stimulatory system and systemic lupus erythematosus

By Chen D-P, Lin W-T and Yu K-H (2022) *Front. Immunol.* 13:946456. doi: 10.3389/fimmu.2022.946456

In the published article, there was an error. The TNFSF4 gene is reverse, in which the wild-type allele of rs1234314 is C rather than G and the wild-type allele of rs45454293 is C rather than G. Originally, the direction of the primer was wrong, so the allele on the sequence we read was followed by the error. Because the complementary base of C is G and rs45454293 is exactly C to G mutation, we didn't find this error at that time. This mistake will cause the opposite result, leading to a misunderstanding about risk allele for SLE. Thus, there are 5 errors in the original manuscript needed to be corrected.

1. A correction has been made to the **Abstract**.

This sentence previously stated: "GG vs. CC: p=0.004; GG+ CG vs. CC: p=0.001"

The corrected sentence appears below: "CC vs. GG: p=0.004; CC+ CG vs. GG: p=0.001".

2. A correction has been made to **Results**, *The analysis of genotype frequencies*.

This sentence previously stated: "Compared to the GG genotype, the subjects with the CC genotype would have a 4.4 times risk of SLE (95% CI =1.577-12.275, p = 0.004), which also had significance based on the dominant model (GG+CG vs. CC: OR = 4.362, 95% CI = 1.727-11.015, p = 0.001)".

The corrected sentence appears below: "Compared to the CC genotype, the subjects with the GG genotype would have a 4.4 times risk of SLE (95% CI =1.577-12.275, p = 0.004), which also had significance based on the dominant model (CC+CG vs. GG: OR = 4.362, 95% CI = 1.727-11.015, p = 0.001)".

3. A correction has been made to **Discussion**, paragraph 3. This sentence previously stated:

“It was shown that the CC genotype of rs1234314 provided a protective effect against allergic rhinitis (50), which was contrary to our result”.

The corrected sentence appears below:

“It was shown that the CC genotype of rs1234314 provided a protective effect against allergic rhinitis (50), which was the same as our result”.

4. In the published article, there was an error in Table 2 as published. The “SNP” and “Allele” columns of the TNFSF4 gene section previously contained the values “rs1234314 C/G and rs45454293 A/G” when they should contain the values “rs1234314 G/C and rs45454293 C/T”. The corrected Table 2 and its caption appears below.

5. In the published article, there was an error in Table 3 as published. The “Genotype” column of the TNFSF4 gene section had “GG” and “CC” in the wrong positions. The corrected Table 3 and its caption appears below.

6. In the published article, there was an error in Table 4 as published. The last row of the “Haplotypes” column previously contained “G”s instead of “C”s.

The corrected Table 4 and its caption appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

TABLE 2 The HWE analysis in control group and the allele frequencies in cases and controls.

| SNP | Position | Allele | Minor allele frequency | | HWE <i>p</i> value | Odds ratio (95%CI) | <i>p</i> ^a value |
|--------------|------------|--------|------------------------|---------|-----------------------|-----------------------|-----------------------------|
| | | | Patient | Control | | | |
| CTLA4 | | | | | | | |
| rs11571315 | 203866178 | C/T | 0.148 | 0.353 | 0.710 | 0.318 (0.179-0.563) | <0.001* |
| rs733618 | 203866221 | T/C | 0.417 | 0.573 | 0.817 | 0.532 (0.335-0.845) | 0.007* |
| rs4553808 | 203866282 | A/G | 0.007 | 0.133 | 0.412 | 0.045 (0.006-0.343) | <0.001* |
| rs11571316 | 203866366 | A/G | 0.157 | 0.220 | 0.654 | 0.661 (0.364-1.201) | 0.172 |
| rs62182595 | 203866465 | A/G | 0.007 | 0.133 | 0.946 | 0.047 (0.006-0.353) | <0.001* |
| rs16840252 | 203866796 | C/T | 0.021 | 0.147 | 0.330 | 0.126 (0.037-0.430) | <0.001* |
| rs5742909 | 203867624 | C/T | 0.079 | 0.140 | 0.370 | 0.524 (0.243-1.130) | 0.095 |
| rs231775 | 203867991 | A/G | 0.325 | 0.349 | 0.999 | 0.899 (0.542-1.488) | 0.678 |
| rs3087243 | 203874196 | G/A | 0.239 | 0.227 | 0.752 | 1.013 (0.589-1.740) | 0.964 |
| rs11571319 | 203874215 | G/A | 0.132 | 0.280 | 0.814 | 0.358 (0.196-0.655) | 0.001* |
| CD28 | | | | | | | |
| rs1879877 | 203705277 | G/T | 0.466 | 0.456 | 0.991 | 1.083 (0.684-1.714) | 0.733 |
| rs3181096 | 203705369 | C/T | 0.247 | 0.284 | 0.220 | 0.826 (0.494-1.383) | 0.468 |
| rs3181097 | 203705416 | G/A | 0.419 | 0.419 | 0.895 | 1.000 (0.630-1.587) | 1.000 |
| rs3181098 | 203705655 | G/A | 0.277 | 0.258 | 0.164 | 1.109 (0.662-1.857) | 0.693 |
| rs56228674 | 203729436 | C/T | 0.033 | 0.040 | 0.979 | 0.828 (0.155-4.405) | 1.000 |
| rs3116496 | 203729789 | T/C | 0.107 | 0.120 | 0.793 | 0.876 (0.323-2.376) | 0.794 |
| PDCD1 | | | | | | | |
| rs5839828 | 241859601 | G/GG | 0.338 | 0.289 | 0.868 | 1.258 (0.761-2.079) | 0.371 |
| rs36084323 | 241859444 | C/T | 0.493 | 0.317 | 0.997 | 2.096 (1.293-3.397) | 0.003* |
| rs41386349 | 241851697 | G/A | 0.222 | 0.180 | 0.470 | 1.302 (0.734-2.308) | 0.366 |
| rs6705653 | 241851407 | T/C | 0.285 | 0.216 | 0.572 | 1.443 (0.847-2.459) | 0.177 |
| rs2227982 | 241851281 | G/A | 0.471 | 0.392 | 0.953 | 1.384 (0.867-2.210) | 0.173 |
| rs2227981 | 241851121 | A/G | 0.261 | 0.223 | 0.297 | 1.232 (0.713-2.127) | 0.454 |
| rs10204525 | 241850169 | C/T | 0.250 | 0.207 | 0.990 | 1.280 (0.642-2.552) | 0.483 |
| ICOS | | | | | | | |
| rs11571305 | 203935403 | G/A | 0.297 | 0.336 | 0.007* | 0.836 (0.504-1.388) | 0.489 |
| rs11889352 | 203935948 | T/A | 0.254 | 0.243 | 0.126 | 1.059 (0.617-1.818) | 0.836 |
| rs11883722 | 203936122 | G/A | 0.418 | 0.421 | 0.491 | 0.985 (0.616-1.576) | 0.951 |
| rs10932029 | 203937045 | T/C | 0.164 | 0.110 | 0.350 | 1.586 (0.789-3.188) | 0.193 |
| rs10932035 | 203959929 | G/A | 0.463 | 0.500 | <0.001* | 0.833 (0.486-1.430) | 0.508 |
| rs10932036 | 203960458 | A/T | 0.047 | 0.056 | 0.154 | 0.844 (0.288-2.475) | 0.757 |
| rs4404254 | 203960563 | T/C | 0.192 | 0.269 | 0.995 | 0.646 (0.368-1.133) | 0.126 |
| rs10932037 | :203960623 | C/T | 0.034 | 0.082 | 0.673 | 0.397 (0.134-1.173) | 0.085 |
| rs10932038 | 203960861 | A/G | 0.035 | 0.077 | 0.561 | 0.432 (0.144-1.298) | 0.125 |
| rs1559931 | 203961006 | G/A | 0.197 | 0.227 | 0.980 | 0.838 (0.467-1.505) | 0.555 |

(Continued)

TABLE 2 Continued

| SNP | Position | Allele | Minor allele frequency | | HWE <i>p</i> value | Odds ratio (95%CI) | <i>p</i> ^a value |
|---------------|-----------|--------|------------------------|---------|-----------------------|-----------------------|-----------------------------|
| | | | Patient | Control | | | |
| rs56259923 | 203961015 | G/T | 0.014 | 0.016 | 0.992 | 0.900 (0.125-6.484) | 1.000 |
| rs4675379 | 203961372 | G/C | 0.156 | 0.161 | 0.598 | 0.967 (0.393-2.381) | 0.942 |
| TNFSF4 | | | | | | | |
| rs1234314 | 173208253 | G/C | 0.514 | 0.360 | 0.395 | 1.881 (1.177-3.005) | 0.008* |
| rs45454293 | 173208097 | C/T | 0.148 | 0.160 | 0.998 | 0.911 (0.482-1.722) | 0.774 |

The position was obtained from Genome Assembly GRCh38.p13. rs: reference SNP; HWE: Hardy-Weinberg equilibrium; 95% CI: 95% confidence interval; *P*^a values of allele frequency were counted from Chi-square test or Fisher's exact test. In the column of "Allele", the bold was referred to minor allele, and the minor allele was referred to the allele with lower frequency in the population containing cases and controls. "*" was expressed as *p*<0.05.

TABLE 3 Genotype frequencies of the significant SNPs in SLE cases and healthy controls.

| SNP | Genotype | Genotype frequency | | Odds ratio 95% CI. | <i>p</i> value |
|--------------|------------------|--------------------|---------|-----------------------|----------------|
| | | Patient | Control | | |
| CTLA4 | | | | | |
| rs11571315 | CC vs. CT vs. TT | | | | 0.001* |
| | TT | 53 | 33 | Ref. | 1.000 |
| | CT | 15 | 31 | 0.301 (0.142-0.641) | 0.001 |
| | CC | 3 | 11 | 0.170 (0.044-0.654) | 0.005** |
| | TT vs. CT + CC | | | 0.267 (0.132-0.539) | <0.001* |
| | TT + CT vs. CC | | | 0.257 (0.068-0.962) | 0.032* |
| rs733618 | CC vs. CT vs. TT | | | | 0.002* |
| | CC | 33 | 15 | Ref. | 1.000 |
| | CT | 18 | 34 | 0.241 (0.104-0.555) | 0.001* |
| | TT | 21 | 26 | 0.367 (0.159-0.849) | 0.018* |
| | CC vs. CT + TT | | | 0.295 (0.142-0.614) | 0.001* |
| | CC + CT vs. TT | | | 0.776 (0.387-1.556) | 0.475 |
| rs4553808 | AA vs. AG vs. GG | | | | <0.001* |
| | AA | 71 | 55 | Ref. | 1.000 |
| | AG | 1 | 20 | 0.039 (0.005-0.298) | <0.001* |
| | GG | 0 | 0 | NA | NA |
| | AA vs. AG+GG | | | 0.039 (0.005-0.298) | <0.001* |
| | AA+AG vs. GG | | | NA | NA |
| rs62182595 | GG vs. AG vs. AA | | | | <0.001* |
| | GG | 69 | 56 | Ref. | 1.000 |
| | AG | 1 | 18 | 0.045 (0.006-0.348) | <0.001** |
| | AA | 0 | 1 | NA | 0.452 |
| | GG vs. AG+AA | | | 0.043 (0.006-0.329) | <0.001* |
| | GG+AG vs. AA | | | NA | 1.000 |
| rs16840252 | CC vs. CT vs. TT | | | | <0.001* |
| | CC | 69 | 53 | Ref. | 1.000 |
| | CT | 1 | 22 | 0.035 (0.005-0.267) | <0.001* |
| | TT | 1 | 0 | NA | 1.000 |
| | CC vs. CT + TT | | | 0.070 (0.016-0.310) | <0.001* |
| | CC + CT vs. TT | | | NA | 0.486 |
| rs5742909 | CC vs. CT vs. TT | | | | 0.051 |
| | CC | 60 | 54 | Ref. | 1.000 |
| | CT | 9 | 21 | 0.386 (0.163-0.914) | 0.027* |
| | TT | 1 | 0 | NA | 1.000 |
| | CC vs. CT + TT | | | 0.429 (0.185-0.991) | 0.044* |
| | CC + CT vs. TT | | | NA | 0.493 |

(Continued)

TABLE 3 Continued

| SNP | Genotype | Genotype frequency | | Odds ratio 95% CI. | p value |
|---------------|------------------|--------------------|---------|-----------------------|---------|
| | | Patient | Control | | |
| rs11571319 | GG vs. AG vs. AA | | | | <0.001* |
| | GG | 58 | 40 | Ref. | 1.000 |
| | AG | 2 | 28 | 0.049 (0.011-0.219) | <0.001* |
| | AA | 8 | 7 | 0.788 (0.265-2.348) | 0.669 |
| | GG vs. AG+AA | | | 0.197 (0.088-0.443) | <0.001* |
| | GG+AG vs. AA | | | 1.295 (0.443-3.784) | 0.636 |
| PDCD1 | | | | | |
| rs36084323 | CC vs. CT vs. TT | | | | 0.013* |
| | TT | 19 | 33 | Ref. | 1.000 |
| | CT | 34 | 31 | 1.905 (0.904-4.014) | 0.089 |
| | CC | 18 | 7 | 4.466 (1.579-12.631) | 0.004* |
| | TT vs. CT+CC | | | 2.377 (1.177-4.798) | 0.015* |
| | TT+CT vs. TT | | | 3.105 (1.206-7.996) | 0.015* |
| TNFSF4 | | | | | |
| rs1234314 | CC vs. CG vs. GG | | | | 0.005* |
| | CC | 20 | 28 | Ref. | 1.000 |
| | CG | 29 | 40 | 1.015 (0.481-2.142) | 0.969 |
| | GG | 22 | 7 | 4.400 (1.577-12.275) | 0.004* |
| | CC vs. CG+ GG | | | 1.519 (0.756-3.051) | 0.239 |
| | CC+ CG vs. GG | | | 4.362 (1.727-11.015) | 0.001* |

95% CI, 95% confidence interval; NA, not applicable. "*" was expressed as p<0.05.

TABLE 4 Genotype frequencies of the significant SNPs in SLE cases and healthy controls.

| Haplotypes | Freq. Cases | Freq. Controls | OR | 95% CI. | p value |
|---|-------------|----------------|-------|-------------|---------|
| A _{rs62182595} T _{rs16840252} | 0.014 | 0.253 | 0.042 | 0.005-0.324 | <0.001 |
| A _{rs62182595} C _{rs16840252} | 0.014 | 0.253 | 0.042 | 0.005-0.324 | <0.001 |
| G _{rs62182595} T _{rs16840252} | 0.014 | 0.280 | 0.037 | 0.005-0.286 | <0.001 |
| C _{rs1234314} C _{rs45454293} | 0.690 | 0.907 | 0.229 | 0.091-0.579 | 0.001 |

Freq., frequency; OR, odds ratio; CI, confidence interval.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.